‚Äč

Industry Symposium 13


13:30-15:00   Hall E

SGLT2 inhibition: Is this a novel approach to prevent the progression of diabetic kidney
disease?

Chair: Gert Mayer, Innsbruck, Austria

Current challenges when treating patients with Type 2 Diabetes & Kidney Disease
Vlado Perkovic, Sydney, Australia
New evidence at the interface of Type 2 Diabetes & Kidney Disease: The EMPA-REG OUTCOME® Trial
Christoph Wanner, Würzburg, Germany
SGLT2 inhibition: How does it work in the kidney?
David Cherney, Toronto, Canada
Implications for clinical practice
Vlado Perkovic, Sydney, Australia

Organised by
BOEHRINGER INGELHEIM & ELI LILLY AND COMPANY DIABETES ALLIANCE


back to timetable

final programme "day by day" - may 21 - 24, 2016

today